![]() This is a strategy many seasoned traders use because it captures decay. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. Given the way analysts feel about Arbutus Biopharma right now, this huge implied volatility could mean there’s a trade developing. ![]() ![]() The net effect has narrowed our Zacks Consensus Estimate for the current quarter from a loss of 21 cents per share to a loss of 18 in that period. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. Clearly, options traders are pricing in a big move for Arbutus Biopharma shares, but what is the fundamental picture for the company? Currently, Arbutus Biopharma is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 36% of our Zacks Industry Rank.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |